Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: patient + 0.25 + web  Related to the article below (Last Update: 8/5/2008)

La Jolla Pharmaceutical Company Reports Second Quarter and Year-to ...
Business Wire (press release), CA -
More information about the Company is available on its Web site: http://www.ljpc.com. The forward-looking statements in this press release involve ...LJPC

WELT ONLINE
CORRECTING and REPLACING Quidel Reports Second Quarter 2008 Results
WELT ONLINE, Germany - Jul 23, 2008
Improvement in gross margin was primarily due to leveraging Quidel?s automated web manufacturing process on an increase in unit volume. ...QDEL
InterMune Reports Second Quarter 2008 Financial Results and ...
CNNMoney.com (press release) - Jul 31, 2008
As a result, the amount of outstanding convertible notes is unchanged, but now consists of two tranches: $85 million of 0.25% convertible notes due 2011 and ...ITMN
Alpha-Linolenic Acid Reduces Risk of Nonfatal MI
Medscape (subscription) - Jul 11, 2008
For the highest vs the lowest decile, ORs for nonfatal MI were 0.41 (95% CI, 0.25 - 0.67) for ALA in adipose tissue and 0.61 (95% CI, 0.42 - 0.88) for ...
Alexion Reports Second Quarter 2008 Results
PR Newswire (press release), NY - Jul 29, 2008
Research and Development: Soliris as a Treatment for Patients with PNH During the second quarter, Alexion completed the 12-week patient dosing in its AEGIS ...ALXN
Avigen Reports Second Quarter 2008 Financial Results
Trading Markets (press release), CA - Jul 30, 2008
"Earlier this week, Avigen sponsored a panel of medical experts who reviewed data from a recent patient survey on spasticity management. ...AVGN - OTC:CMTX
InvestSource Inc.: Hall-of-Fame Jockey Jorge Velasquez Appointed ...
Trading Markets (press release), CA - Jul 14, 2008
The data are regularly monitored by a remotely located medical professional, who watches for any abnormal readings that may signal a change in the patient's ...PINK:HYII - NGSX - BHRT
Source: Google News

Neurologic Complications of 405 Consecutive Continuous Axillary Catheters -
BD Bergman, JR Hebl, J Kent, TT Horlocker - Anesthesia & Analgesia, 2003 - IARS
... or cardiac dysrhythmias. In 1 patient, 0.25% bupivacaine had been infused
at a rate of 12 mL/h for 5 days. Scant data are available ...

Investigation of a nosocomial outbreak of Pseudomonas aeruginosa pneumonia in an intensive care unit … -
… Moore, MD Curran, R Graham, CH Web, KG Lowry, PG … - Journal of Hospital Infection, 1995 - Elsevier
... Transmission may occur through direct patient-to-patient contact, en ... in 0.25 M EDTA,
and the mixture was placed on ice for 60 min, prior to the addition of 7.50 ...

Patient-Controlled Epidural Analgesia During Labor: The Effects of the Increase in Bolus and Lockout … -
JM Bernard, D Le Roux, L Vizquel, A Barthe, JM … - Anesthesia & Analgesia, 2000 - IARS
... Rescue analgesia was provided with 6 mL of 0.25% bupivacaine. Patient satisfaction
and pain were scored on verbal and visual analog scales. ...

The Efficacy of Intravenous 0.15 Versus 0.25 mg/kg Intraoperative Morphine for Immediate … -
D Fletcher, M Pinaud, P Scherpereel, N Clyti, M … - Anesthesia & Analgesia, 2000 - IARS
... Included in the study were 248 patients (Table 1). One patient in the 0.15-mg and
two patients in the 0.25-mg groups were excluded from the study for major ...

Bupivacaine Wound Instillation via an Electronic Patient-Controlled Analgesia Device and a Double- … -
B Fredman, E Zohar, A Tarabykin, A Shapiro, A Mayo … - Anesthesia & Analgesia, 2001 - IARS
... After major abdominal surgery performed through a 20-cm incision, repeated 0.25%
bupivacaine wound instillation via an electronic patient-controlled analgesia ...

Use of Regression Modeling to Simulate Patient-Specific Decision Analysis for Patients with … -
JA Johnston, MH Eckman - Medical Decision Making, 2003 - mdm.sagepub.com
... investigators have described the use of a Web-based interface ... of QALE for the Ohio
Medicaid patient cohort ... The mean ( SD) value for QALE was 0.25 ( 0.73) quality ...

… This article has been selected for the open discussion forum on the STS Web site: http://www. sts. … -
A Yamaguchi, T Ino, H Adachi, S Murata, H Kamio, M … - The Annals of Thoracic Surgery, 1998 - Soc Thorac Surgeons
... discussion forum on the STS Web site: http ... fibrillation (2 patients), and
cerebrovascular disease (1 patient). ... mean EF increased significantly from 0.25 0.06 ...

A Comparison of the Analgesic Efficacy of 0.25% Levobupivacaine Combined with 0.005% Morphine, 0.25% … -
JC Crews, AH Hord, DD Denson, C Schatzman - Anesthesia & Analgesia, 1999 - IARS
... 1 patient allocation. The three treatment groups were as follows: a combination
group, which received a continuous epidural infusion of levobupivacaine 0.25% ( ...

Providing a web-based online medical record with electronic communication capabilities to patients … -
SE Ross, LA Moore, MA Earnest, L Wittevrongel, CT … - J Med Internet Res, 2004 - pubmedcentral.nih.gov
... SPPARO provides a secure Web interface to three components: the medical record,
an ... For patient satisfaction, a difference of 0.25 points in the mean ...

Assessing a system to detect patient motion in SPECT imaging using stereo optical cameras
MA Gennert, PP Bruyant, MV Narayanan, MA King - Nuclear Science Symposium Conference Record, 2002 IEEE, 2002 - ieeexplore.ieee.org
... RMS error of VTS axial motion is 0.25cm. ... Low cost Logitech web cameras are used to
acquire stereo image ... color patches, as would be done with a real patient. ...

Source: Google Scholar
 

Patients Smelling For First Time In Their Lives Results From First Characterization Of Abnormalities In Congenital Loss Of Smell

New discoveries about the biochemical basis of the majority of cases of the congenital inability to smell any odor, no matter how strong, have enabled their discoverer, Dr. Robert I. Henkin, director of The Taste and Smell Clinic in Washington, DC, to treat such patients, enabling them to smell something for the first time in their lives.

These patients respond with amazement, Dr. Henkin told fellow scientists gathered at Experimental Biology 2007 meeting in Washington. “Until the treatment began to take effect, they had never experienced the olfactory world that surrounds us all, and it is with excitement that they quickly begin to learn what different things smell like and to relate those odors to objects they have known all their lives,” says Dr. Henkin.

Dr. Henkin’s Experimental Biology presentation, on April 30, is part of the scientific program of The American Physiological Society. His study is the first to characterize the biochemical abnormalities in these patients and the first to successfully treat patients using this new understanding.

Article continues below and (thank you)

 

In the United States alone, there are about 400,000 people who have never smelled anything in their lives. (This does not include those who lose their once normal smell function because of illness or accident.)  A relatively small percentage - 12 percent - of individuals with congenital smell loss have multiple anatomical abnormalities of the brain and other organs. The vast majority - 88 percent - of individuals with congenital smell loss, however, do not have any such obvious organ abnormalities and their olfactory nerves and the brain regions that process olfactory information are intact.

Why, then, have they never been able to smell?

In order to answer that question, Dr. Henkin examined these seemingly normal patients’ nasal mucus, the fluid that bathes the olfactory nerve receptors. From earlier studies in his laboratory, Dr. Henkin knew that the nasal mucus contains growth factors responsible for olfactory stem cell maturation and function. Without these growth factors, olfactory receptor cells can not maintain normal cell function. As he suspected, the nasal mucus from these patients was deficient in these important growth factors.

The studies also found a double whammy in these patients’ nasal mucus. Normal mucus contains not only growth factors to allow new olfactory receptor cells to function, it also contains death factors that kill the aging receptor cells (a normal process of programmed cell death, or apoptosis), making way for the new. The congenital smell loss patients had five to 10 times the concentration of these death factors as do people who can smell. That guaranteed that the high concentration of death factor would destroy any receptor cell growth that was able to take place.

After determining the family of enzymes to which the growth and death factors belong and defining the biochemical pathway responsible for these factors, Dr. Henkin was able to treat these patients with PDE inhibitors that increase the concentration of growth factors and inhibit the secretion o death factors in nasal mucus. The treatment has been successful in restoring smell function in some of these patients, with the higher the dose and longer the use having the greatest effect.

 

APS Presentation 12:30 p.m. EDT, Monday, April 30
Pressroom presentation 10:30 a.m. EDT, Monday, April 30
Embargoed to the date and time above

Media Contact
Sarah Goodwin
(202) 249-4165 April 28-May 2

 
Google
Web www.iconocast.com
 
 
Source for News : URL: http://www.medicalnewstoday.com and Reuters
Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast